Pfizer Completes Acquisition of Encysive Pharmaceuticals Inc.

  
    
  
  
    
      Pfizer Inc (NYSE:PFE) today announced that it has completed the 
      acquisition of all remaining outstanding shares of common stock of 
      Encysive Pharmaceuticals Inc. (NASDAQ:ENCY) through a merger of Pfizer�s 
      wholly-owned subsidiary, Explorer Acquisition Corp., with and into 
      Encysive. Encysive is now a wholly-owned subsidiary of Pfizer.
    
    
      In the merger, each share of Encysive�s 
      outstanding common stock was cancelled and (except for shares held by 
      Encysive, Pfizer or by their wholly-owned subsidiaries or by holders who 
      properly exercised their appraisal rights under Delaware law) converted 
      into the right to receive $2.35 per share in cash, without interest and 
      less any required withholding taxes. Prior to the merger, Explorer 
      Acquisition Corp. acquired approximately 85.33% of the outstanding 
      Encysive shares by tender offer. Encysive's common stock will cease to 
      be traded on the NASDAQ Global Market by the close of the market today.
    
    
      Pfizer has appointed Computershare Trust Company, N.A. as the paying 
      agent for payment of the merger consideration. The paying agent will 
      mail instructions to former Encysive stockholders outlining the steps to 
      be taken to obtain the merger consideration. Stockholders do not need to 
      take any action regarding their shares until contacted by the paying 
      agent.